Connect Biopharma's rademikibart faces asthma test after enrollment closes
Seabreeze STAT completed enrollment at its 160-patient target, and Connect Biopharma now heads toward a September topline readout testing whether rademikibart cuts treatment failure after an acute asthma flare.
Executive Summary
- Connect Biopharma has closed enrollment in a placebo-controlled Phase 2 trial testing whether adding rademikibart to standard care during an acute asthma exacerbation lowers the rate of treatment failure, with topline results expected within weeks.
- The trial finished enrolling at its original target with no change in size, moved to a non-recruiting status, and its completion date shifted later within the same quarter, all consistent with a study wrapping up on a slightly extended internal timeline rather than one in distress.
- No biologic is currently approved specifically as an add-on for an acute asthma exacerbation, so a result that clears the trial's own bar would represent evidence for a treatment category that does not yet exist, while a null result would leave that gap unaddressed by this mechanism.
- Rademikibart competes on mechanism with a handful of IL-13/IL-4-pathway antibodies advancing in adjacent obstructive-airway indications, none of which have generated a placebo-controlled acute-exacerbation add-on result of their own yet.
The trial
Seabreeze STAT Asthma (NCT06940141) is a randomized, double-blind, placebo-controlled Phase 2 study that enrolled 160 adult and adolescent participants with physician-diagnosed asthma who presented with an acute exacerbation and a peripheral blood eosinophil count of at least 300 cells per microliter. Participants received either a single subcutaneous dose of rademikibart or placebo on top of standard-of-care systemic corticosteroids. The primary endpoint is treatment failure rate within 28 days of randomization, and the key secondary endpoint is post-bronchodilator FEV1, a lung-function measure, at week 1. NCT06940141+1Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)NCT06940141Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study ...Jun 17, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What Connect Biopharma said
Connect Biopharma announced completion of enrollment on June 17, 2026, and said it expects to report topline data in early September 2026. "Completion of enrollment in our Seabreeze STAT Asthma study marks another significant step in our mission to deliver the first biologic to treat patients suffering from an acute exacerbation of asthma," said Barry Quart, Pharm.D., chief executive officer and director of Connect Biopharma. The company said it plans to meet with the FDA to align on a Phase 3 program later in 2026 if the data support it. ConnectConnect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study ...Jun 17, 2026
Operational read
The trial's primary completion date moved from an original April 2026 target to June 2026 and then to July 13, 2026, a cumulative shift of roughly three months, while enrollment held flat at its 160-patient target throughout. That combination, enrollment reaching target with no size change and a status move to Active, not recruiting timed to the close of enrollment, reads as a trial finishing on a slower internal calendar rather than one that struggled to fill or that shrank its ambitions. NCT06940141Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)NCT06940141
The competitive frame
No mechanism has an approved biologic add-on therapy for acute asthma exacerbations, and rademikibart's own field, IL-13 and the related IL-4 receptor alpha pathway, shows a low failure rate in Phase 2 asthma trials generally, with roughly 1 of 18 completed or terminated Phase 2 programs in that class ending in failure. The closest mechanism-matched comparators, including dupilumab, stapokibart, and lunsekimig, are advancing in chronic obstructive pulmonary disease rather than the acute-exacerbation setting rademikibart is testing, leaving this readout without a direct precedent in the same clinical scenario.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.